{
    "id": 22272,
    "fullName": "ATRX loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "ATRX loss indicates loss of the ATRX gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 546,
        "geneSymbol": "ATRX",
        "terms": [
            "ATRX",
            "JMS",
            "MRX52",
            "RAD54",
            "RAD54L",
            "XH2",
            "XNP",
            "ZNF-HX"
        ]
    },
    "variant": "loss",
    "createDate": "05/09/2016",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6204,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",
            "molecularProfile": {
                "id": 22832,
                "profileName": "ATRX loss"
            },
            "therapy": {
                "id": 942,
                "therapyName": "Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5444,
                    "pubMedId": 26936505,
                    "title": "ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936505"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6203,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",
            "molecularProfile": {
                "id": 22832,
                "profileName": "ATRX loss"
            },
            "therapy": {
                "id": 1074,
                "therapyName": "Irinotecan",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5444,
                    "pubMedId": 26936505,
                    "title": "ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936505"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6202,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",
            "molecularProfile": {
                "id": 22832,
                "profileName": "ATRX loss"
            },
            "therapy": {
                "id": 1009,
                "therapyName": "Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5444,
                    "pubMedId": 26936505,
                    "title": "ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936505"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13384,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).",
            "molecularProfile": {
                "id": 22833,
                "profileName": "ATRX loss IDH1 mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6205,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339).",
            "molecularProfile": {
                "id": 22833,
                "profileName": "ATRX loss IDH1 mut"
            },
            "therapy": {
                "id": 4093,
                "therapyName": "Gemcitabine + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5446,
                    "pubMedId": 26853339,
                    "title": "Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26853339"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13389,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "ATRX deficiency in combination with IDH mutation aids in the diagnosis of astrocytoma (NCCN.org).",
            "molecularProfile": {
                "id": 29113,
                "profileName": "ATRX loss IDH2 mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 22832,
            "profileName": "ATRX loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22833,
            "profileName": "ATRX loss IDH1 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29113,
            "profileName": "ATRX loss IDH2 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}